Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis

Han Shan; Zihan Guo; Xuan Ye; Qiong Du; Jiyong Liu; Mengmeng Wang

doi:10.1007/s44446-025-00042-2

Citations

386

Views

Abstract not available for this publication.

Cite this Article (APA)

Han, S., Zihan, G., Xuan, Y., Qiong, D., Jiyong, L., Mengmeng, W. (2025). Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis. Saudi Pharmaceutical Journal. https://doi.org/10.1007/s44446-025-00042-2

Rabia Gul; Hamid Bashir; Muhammad Sarfraz; Ahson Jabbar Shaikh; Yousef A. Bin Ja · 2024

cites

396

Rise of implantable drugs: A chronicle of breakthroughs in drug delivery systems

Kampanart Huanbutta; Vivek Puri; Ameya Sharma; Inderbir Singh; Pornsak Sriamorns · 2024

cites

391

A systematic review of obesity burden in Saudi Arabia: Prevalence and associated co-morbidities

Hussain A. Al-Omar; Ali Alshehri; Saleh A. Alqahtani; Hana Alabdulkarim; Ali Alr · 2024

cites

394

Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management …